Core Insights - Citius Oncology has entered into an exclusive distribution agreement with Uniphar to expand access to LYMPHIR in Europe, marking its third international distribution partnership [1][2] - The agreement allows Uniphar to manage access and distribution of LYMPHIR in specific territories in Western and Eastern Europe through country-specific managed access programs [1] - LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and is not yet approved for commercial use outside the United States [1][2] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing and commercializing novel targeted oncology therapies [2] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [2] - Citius Oncology has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use [2] Product Information - LYMPHIR (denileukin diftitox-cxdl) is indicated for use in Stage I-III CTCL after at least one prior systemic therapy [1] - The drug works by binding to IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis [1] - In 2021, denileukin diftitox received regulatory approval in Japan for treating relapsed or refractory CTCL and peripheral T-cell lymphoma [1] Distribution Partner - Uniphar is an international healthcare services company that supports over 200 pharmaceutical and medical technology manufacturers [2] - The partnership with Citius Oncology aims to improve patient outcomes for those with relapsed or refractory CTCL [1][2] - Uniphar operates across 180 countries and integrates various services to support the full product lifecycle from research to commercialization [2]